Back to top
more

LAVA Therapeutics (LVTX)

(Delayed Data from NSDQ)

$2.84 USD

2.84
114,990

-0.19 (-6.27%)

Updated May 6, 2024 04:00 PM ET

After-Market: $2.92 +0.08 (2.82%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 0% and 105.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aravive (ARAV) delivered earnings and revenue surprises of 60% and 27.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of 10.53% and 15.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall

by Zacks Equity Research

Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.

LAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection

by Zacks Equity Research

LAVA's (LVTX) shares soar as partner J&J (JNJ) selects a lead candidate for development in clinical studies for cancer.

Is a Beat Likely for Cooper Companies (COO) in Q2 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.

Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -10.53% and 23.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -37.50% and 59.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates

by Zacks Equity Research

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Will LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

LAVA Therapeutics N.V. (LVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 100% and 6.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -22.47% and 0.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Seagen's (SGEN) Portfolio of Drugs Help Combat Rivalry?

by Zacks Equity Research

Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.

Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223

by Zacks Equity Research

Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.

LAVA Therapeutics N.V. (LVTX) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

LAVA Therapeutics N.V. (LVTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 49.18% and 53.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Fstar Therapeutics, Inc. (FSTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of -41.94% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?